Please use this identifier to cite or link to this item:
Title: Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
Austin Authors: Seymour, John F;Marcus, Robert;Davies, Andrew;Gallop-Evans, Eve;Grigg, Andrew P ;Haynes, Andrew;Herold, Michael;Illmer, Thomas;Nilsson-Ehle, Herman;Sökler, Martin;Dünzinger, Ulrich;Nielsen, Tina;Launonen, Aino;Hiddemann, Wolfgang
Affiliation: Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, Australia
Kings College Hospital, London, UK
F. Hoffmann-La Roche Ltd., Basel, Switzerland
Austin Health, Heidelberg, Victoria, Australia
Cancer Research UK Centre, University of Southampton, Southampton, UK
Velindre Cancer Centre, Cardiff, UK
Nottingham University Hospitals NHS Trust, Nottingham, UK
HELIOS-Klinikum Erfurt, Germany
BAG Freiberg-Richter, Jacobasch, Illmer and Wolf, Dresden, Germany
Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
Eberhard-Karls-University Tübingen, Tübingen, Germany
Roche Pharma AG, Grenzach-Wyhlen, Germany
Department of Medicine III, Ludwig-Maximilians-University, München, Germany
Issue Date: May-2020
Publication information: Haematologica 2020; 105(5): 1465
DOI: 10.3324/haematol.2020.246991
PubMed URL: 32358081
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 28, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.